Breaking News Instant updates and real-time market news.

ONCE

Spark Therapeutics

$55.94

-21.69 (-27.94%)

14:26
08/07/18
08/07
14:26
08/07/18
14:26

Spark Therapeutics downgraded to Underperform from Outperform at Credit Suisse

Credit Suisse downgraded Spark Therapeutics to Underperform from Outperform and cut its price target to $48 from $98.

  • 07

    Aug

  • 10

    Sep

ONCE Spark Therapeutics
$55.94

-21.69 (-27.94%)

08/07/18
SBSH
08/07/18
UPGRADE
SBSH
Buy
Citi upgrades Spark Therapeutics to Buy with shares down nearly 30%
Citi analyst Mohit Bansal upgraded Spark Therapeutics to Buy from Neutral amid today's post-earnings selloff. The analyst maintains an $85 price target for the shares. The company's update this morning on its hemophilia A gene therapy was "incrementally positive and better than our expectations," Bansal tells investors in a research note. The analyst feels investors should not be too concerned about the immune flare in two patients as he thinks these patients could be managed with prophylactic use of steroids. Other gene therapy players are using prophylactic steroids and it was a bit surprising that Spark did not use prophylactic steroid in the first place, the analyst writes. He views today's selloff as a buying opportunity saying the data in five of seven patients are better than his expectations. Bansal notes that Spark will employ a prophy strategy going forward. The analyst also views the company as a potential takeover candidate. He pegs Spark's buyout valuation at $130 per share. The stock in midday trading is down 29%, or $22.49, to $55.12.
08/07/18
LEER
08/07/18
NO CHANGE
Target $55
LEER
Market Perform
Spark Therapeutics price target lowered to $55 from $74 at Leerink
08/07/18
LEER
08/07/18
NO CHANGE
Target $55
LEER
Market Perform
Spark Therapeutics price target lowered to $55 from $74 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Spark Therapeutics to $55 from $74 based on a reduction in his PoS for SPK-8011 to 15% from 25% previously. The analyst notes that SPK-8011 in hemophilia A continues to miss its target product profile of consistent factor VIII expression above 12% of normal levels, confirming his concerns about immunogenicity to the SPK-100 vector which arose after the first SPK-8011 data update at ASH 2017. Schwartz reiterates a Market Perform rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.